<sup>13</sup>C‐ethanol breath test reveals impaired alcohol metabolism in patients with <scp>Helicobacter pylori</scp> infection

Suzuki, Masayuki; Maruyama, Katsuya; Suzuki, Hidekazu; Tanaki, S.; Suzuki, Kumi; Ishii, Hiromasa

doi:10.1111/j.1365-2036.2004.02020.x

Cited by 5 publications

(5 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Evidence showed that ethanol exposure can potentiate the suppressive effects of HCV on innate immunity, which activates viral spread in the liver, and finally leads to impairments in adaptive immunity [36]. Moreover, the first‐pass metabolism of ethanol is attenuated in patients with H. pylori infection due to reduced alcohol dehydrogenase activity in the inflamed gastric mucosa [37]. However, more convincing evidence is needed to obtain more information on this issue.…”

Section: Discussionmentioning

confidence: 99%

First‐line Helicobacter pylori eradication among patients with chronic liver diseases in Taiwan

Tsai

Liang

Lee

et al. 2016

The Kaohsiung J of Med Scie

View full text Add to dashboard Cite

Helicobacter pylori eradication in patients with chronic liver diseases (CLDs) and liver cirrhosis is seldom reported. This study aimed to assess the efficacy of 7-day standard triple therapy in patients with CLD including cirrhosis and to investigate the clinical factors influencing the success of eradication. A total of 592 H. pylori-infected patients, who received 7-day standard first-line triple therapy between January 1, 2014, and December 31, 2014, were recruited. Patients were divided into two groups: CLD group (N=136) and non-CLD group (N=456). The eradication rates attained by the CLD and non-CLD groups were 86.0% and 84.2%, respectively, in the per-protocol analysis (p=0.606). The eradication rates of liver cirrhosis and noncirrhosis CLD were 88.5% and 84.3%, respectively (p=0.783). The adverse events were similar between the two groups (8.8% vs. 9.2%, p=0.891). Compliance between the two groups was good (99.3% vs. 99.6%, p=0.670). The univariate analysis showed male sex to be the significant clinical factor in the non-CLD group (p=0.001) and alcohol consumption to be the significant clinical factor influencing H. pylori eradication rate in patients with CLD (p=0.022). Alcohol consumption was the only significant factor influencing H. pylori eradication in multivariate analysis (odds ratio=3.786, p=0.031). The results of this study suggest that H. pylori eradication rates in patients with CLD may be comparable with non-CLD patients. Alcohol consumption was the significant factor influencing H. pylori eradication in patients with CLD.

show abstract

Section: Discussionmentioning

confidence: 99%

First‐line Helicobacter pylori eradication among patients with chronic liver diseases in Taiwan

Tsai

Liang

Lee

et al. 2016

The Kaohsiung J of Med Scie

View full text Add to dashboard Cite

show abstract

“…Seventeen asymptomatic volunteers diagnosed as H. pylori-positive by the C 13 -urea breath test were orally administered urease-specific IgY for 4 weeks and then the breath test values were significantly decreased [13]. In a 53-year-old female administered urease-specific IgY, when combined with antacids, ameliorated gastric inflammation [14]. This article will focus on introducing the novel approaches on developing an effective, safe, and natural IgY against the H. pylori that may enable the future eradication of the organism as a significant human pathogen.…”

Section: Introductionmentioning

confidence: 99%

Immunoglobulin: A Natural Way to Suppress <i>Helicobacter pylori</i> in Humans

Abdou¹,

Ahmed²,

Yamashita³

et al. 2014

Health

View full text Add to dashboard Cite

The use of immunoglobulin is successfully applied in different areas of research, diagnostics, medical application and biotechnology. Egg yolk immunoglobulin (IgY) can successfully compete with immunoglobulin (IgG) produced in the blood of mammals. Recently, successful progresses have been achieved in Japan through industrialization of IgY technology. Using IgY has been shown to provide a safer, more efficient and less expensive method for managing disease-causing pathogens. Helicobacter pylori (H. pylori), a spiral Gram-negative microaerophilic pathogen, it infects over 50% of the population worldwide, and is recognized as the etiologic agent of gastritis, peptic ulcer, and has been linked to the development of gastric adenocarcinoma and mucosa associated lymphoid tissue lymphoma. It is found that urease is the most abundant protein of H. pylori. Urease is recognized as an essential factor in the organism colonization of the gastric mucosa. The eradication of H. pylori by administration of oral antimicrobials is not always successful and may be associated with adverse effects. Therefore, several treatment regimens have emerged to cure H. pylori infection. Accordingly, a novel approach in prevention and reduction of H. pylori infection has been reported based on production of urease-specific immunoglobulin that can suppress the bacterial colonization through urease-binding by anti-H. pylori urease IgY (IgY-urease). The use of IgY against a pathogenic factor of H. pylori will be a prudent way to suppress the infection.

show abstract

“…This method is accurate and reliable but has the disadvantage of being invasive. We previously reported that ethanol degradation into carbon dioxide could be evaluated by measuring 13 CO 2 content in breath samples after the oral intake of [ 13 C]‐ethanol 2 . In that study, [ 13 C]‐ethanol breath test (EBT) was performed after the oral intake of a small amount of ethanol (0.08 g) by healthy volunteers.…”

Section: Introductionmentioning

confidence: 99%

“…We previously reported that ethanol degradation into carbon dioxide could be evaluated by measuring 13 CO 2 content in breath samples after the oral intake of [ 13 C]-ethanol. 2 In that study, [ 13 C]-ethanol breath test (EBT) was performed after the oral intake of a small amount of ethanol (0.08 g) by healthy volunteers. We are now interested in investigating the metabolic response after ingestion of a large amount of ethanol (4 g).…”

Section: Introductionmentioning

confidence: 99%

Evaluation of alcohol metabolism in humans using the non‐invasive [¹³C]‐ethanol breath test – influence of gender, Helicobacter pylori infection and polymorphism of alcohol‐oxidizing enzymes

Suzuki

Tanaka

Komatsu

et al. 2006

Ali Pharm Thera Symp Ser

Self Cite

View full text Add to dashboard Cite

Summary Background The [13C]‐ethanol breath test (EBT) has been proposed as a novel non‐invasive laboratory test to detect the degradation of ethanol into CO2. However, this method has not yet been evaluated clinically. Aim To investigate the factors that influence [13C]‐EBT. Methods Twenty‐six healthy volunteers were instructed to drink 100 mL of beer (4 g ethanol) containing 100 μL of [13C]‐ethanol. Breath samples were collected every 15 min before and after the intake of ethanol solution and 13CO2‐enrichment was measured using mass spectrometry. CO2 excretion was then calculated, and the results were evaluated using kinetic parameters (Tmax, Cmax, AUC). Results T max (min) was significantly shorter in men than in women but not Cmax and AUC. Infection with H. pylori had no impact on all kinetic parameters. Genetic alcohol dehydrogenase (ADH) polymorphisms did not affect 13CO2 excretion, but Cmax (11.1 ± 3.4% dose/h, n = 16) and AUC (10.5 ± 3.4% dose) were slightly increased in aldehyde dehydrogenase (ALDH)‐deficient individuals (heterozygote of ALDH2*2) (13.2 ± 3.2 and 12.9 ± 4.5, respectively; n = 10). Conclusions [13C]‐EBT is capable of assessing the metabolic processing of 100 mL beer in a non‐invasive way. Kinetic parameters are partially influenced by ALDH polymorphism but not by gender, H. pylori infection or ADH polymorphism.

show abstract

¹³C‐ethanol breath test reveals impaired alcohol metabolism in patients with Helicobacter pylori infection

Cited by 5 publications

References 22 publications

First‐line Helicobacter pylori eradication among patients with chronic liver diseases in Taiwan

First‐line Helicobacter pylori eradication among patients with chronic liver diseases in Taiwan

Immunoglobulin: A Natural Way to Suppress <i>Helicobacter pylori</i> in Humans

Evaluation of alcohol metabolism in humans using the non‐invasive [¹³C]‐ethanol breath test – influence of gender, Helicobacter pylori infection and polymorphism of alcohol‐oxidizing enzymes

Contact Info

Product

Resources

About

13C‐ethanol breath test reveals impaired alcohol metabolism in patients with Helicobacter pylori infection

Cited by 5 publications

References 22 publications

First‐line Helicobacter pylori eradication among patients with chronic liver diseases in Taiwan

First‐line Helicobacter pylori eradication among patients with chronic liver diseases in Taiwan

Immunoglobulin: A Natural Way to Suppress &lt;i&gt;Helicobacter pylori&lt;/i&gt; in Humans

Evaluation of alcohol metabolism in humans using the non‐invasive [13C]‐ethanol breath test – influence of gender, Helicobacter pylori infection and polymorphism of alcohol‐oxidizing enzymes

Contact Info

Product

Resources

About

¹³C‐ethanol breath test reveals impaired alcohol metabolism in patients with Helicobacter pylori infection

Immunoglobulin: A Natural Way to Suppress <i>Helicobacter pylori</i> in Humans

Evaluation of alcohol metabolism in humans using the non‐invasive [¹³C]‐ethanol breath test – influence of gender, Helicobacter pylori infection and polymorphism of alcohol‐oxidizing enzymes